Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > High on Nano: Cannabinoid Nanoparticles to Treat the Primary Cause of Heart Attack and Stroke

Abstract:
Only two years ago an American-Dutch research effort was the first trialling nanotherapy in cardiovascular patients. Since then they took some remarkable steps towards the use of a combination of endogenous nanoparticles and cannabinoids to treat atherosclerosis. Ground-breaking projects demand innovative ways to create publicity and gather funding. The non-profit organization High on Nano aims to crowd fund a documentary about this topic to support the research.

High on Nano: Cannabinoid Nanoparticles to Treat the Primary Cause of Heart Attack and Stroke

Amsterdam, Netherlands | Posted on December 4th, 2013

The development of nanotechnologies to encapsulate drugs in tiny nanoparticles has witnessed tremendous growth in the last two decades. These nanoparticles are designed for accurate delivery of imaging agents and/or drugs at diseased sites, increasing precision hits while hopefully lowering side effects. Unfortunately the large amount of promising research projects -mainly focusing on oncologic targets- only reported limited clinical successes so far.

For the exploration of nanotechnology in cardiovascular medicine the Dutch chemist Willem Mulder founded the Nanomedicine Laboratory at the Icahn School of Medicine at Mount Sinai in 2006. The nanoparticle platforms his team develops are designed to specifically target atherosclerotic plaques, the underlying cause of cardiovascular disease. In cooperation with the Academic Medical Center in Amsterdam the first-in-man trials with synthetic nanoparticles were initiated already in 2011. In preclinical studies the exploitation of endogenous nanoparticles has shown promise in the context of cardiovascular disease, as such nanoparticles exhibit a natural affinity for atherosclerotic plaques. These particles create an attractive and natural drug delivery platform for atherosclerotic targets.

One of the potent anti-atherosclerotic drug classes they investigate is cannabinoids. In 2005 a seminal study published in the journal Nature demonstrated that low dose oral cannabinoid therapy reduces the progression of atherosclerosis in mice. However, research activity in this area has been relatively subdued. This may be -in part- attributed to psychotropic side effects, and poor specificity and bioavailability of orally administered cannabinoids. To overcome these limitations, nanoparticle formulations may offer an attractive alternative.

Atherosclerosis is also known as ‘hardening' of the arteries. It is a result of genetics, high cholesterol, high blood pressure and smoking cigarettes. It is a common underlying cause of cardiovascular diseases, including heart attack and stroke, and represents the highest expenditure of the world health care (app €198 billion in EU and $300 billion in the US).

Every year about 1,3 million people die from cardiovascular disease in the US and 1,6 million in Europe.

In patients who suffered a heart attack the recurrence risk of an acute coronary syndrome is high, particularly within the first three years when recurrence rates are up to over 20%.

The Dutch Non-profit organization High on Nano was founded on October 28th. Their goal is to popularise the work of Willem Mulder and his teams by developing a documentary (series) about his work.

####

About www.HighonNano.com
To support this project, non-profit organization High on Nano was recently founded. Their aim is to familiarize the general public with this exciting field and establish innovative mechanisms to help fund the research. The first step is crowd funding a documentary to show the world what is going on in the field of 21st century nanomedicine. They hope this process, and the resulting publicity, ultimately open up ways to fund part of the research.

For more information, please click here

Contacts:
Gert van Kempen
Chairman
Non-profit Organization High on Nano

http://www.facebook.com/HighonNano

Copyright © www.HighonNano.com

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related Links

Article:

Clinical trials:

Clinical trials:

Article:

Abstract:

Related News Press

News and information

Princeton-led team discovers unexpected quantum behavior in kagome lattice:Experiments suggest evidence for novel patterns of electronic charge distribution in a kagome material whose handedness can be manipulated with a magnetic field June 18th, 2021

Atomic-scale tailoring of graphene approaches macroscopic world June 18th, 2021

Compact quantum computer for server centers: Researchers build smallest quantum computer yet based on industry standards June 18th, 2021

Changing a 2D material's symmetry can unlock its promise: Jian Shi Research Group engineers material into promising optoelectronic June 18th, 2021

Videos/Movies

Rice lab peers inside 2D crystal synthesis: Simulations could help molecular engineers enhance creation of semiconducting nanomaterials June 11th, 2021

CEA-Leti Introduces Plastic mmWave System for Applications Requiring Ultra-Low Latency and Ultra-High-Speed Connectivity: Low-Cost Gb/s Connectivity Overcomes Limits of Copper Wire and Optical Fiber For Automotive, Aeronautics, Telecom, Industry 4.0 and Healthcare Uses May 28th, 2021

Sensors developed at URI can identify threats at the molecular level: More sensitive than a dog's nose and the sensors don't get tired May 21st, 2021

Fast-acting, color-changing molecular probe senses when a material is about to fail March 25th, 2021

VC/Funding/Angel financing/Loans/Leases/Crowdfunding

180 Degree Capital Corp. Reports +14.2% Growth in Q1 2021, $10.60 Net Asset Value Per Share as of March 31, 2021, and Developments From Q2 2021 May 11th, 2021

180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021

180 Degree Capital Corp. Reports +6.7% Growth in Q4 2020, $9.28 Net Asset Value per Share as of December 31, 2020, and Developments from Q1 2021 Including Expected Investment in a Planned SPAC Sponsor February 22nd, 2021

Nanomedicine

AI app could help diagnose HIV more accurately: Pioneering technology developed by UCL (University College London) and Africa Health Research Institute (AHRI) researchers could transform the ability to accurately interpret HIV test results, particularly in low- and middle-income June 18th, 2021

'Nanodecoy' therapy binds and neutralizes SARS-CoV-2 virus June 18th, 2021

Turning the heat on: A flexible device for localized heat treatment of living tissues June 11th, 2021

Arrowhead Pharmaceuticals to Participate in Upcoming Conferences June 2nd, 2021

Announcements

Proliferation of electric vehicles based on high-performance, low-cost sodium-ion battery:A large-capacity anode material is developed for sodium-ion batteries by using low-cost silicone-based oil. This process, if commercialized, is expected to significantly reduce manufacturing June 18th, 2021

AI app could help diagnose HIV more accurately: Pioneering technology developed by UCL (University College London) and Africa Health Research Institute (AHRI) researchers could transform the ability to accurately interpret HIV test results, particularly in low- and middle-income June 18th, 2021

Compact quantum computer for server centers: Researchers build smallest quantum computer yet based on industry standards June 18th, 2021

Changing a 2D material's symmetry can unlock its promise: Jian Shi Research Group engineers material into promising optoelectronic June 18th, 2021

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project